Parabilis Medicines Starts Dose-Ranging FAP Cohort in Phase 1/2 Trial

The company initiated a zolucatetide dose-ranging cohort for FAP, citing early reductions in duodenal polyp burden in two patients and a favorable safety profile to date. Additional FAP and desmoid data are anticipated in Q1 2027.